312 results about "Gene carrier" patented technology

The invention generally relates to polymeric particles suitable for transporting bioactive agents across mucosal barriers. The invention also relates to methods of making and using those polymeric particles.

A biodegradable, mixed polymeric micelle used to deliver a selected nucleic acid into a targeted host cell contains an amphiphilic polyester-polycation copolymer and an amphiphilic polyester-sugar copolymer. The polyester-polycation copolymer forms an electrostatic interaction with polyanionic nucleic acids, and the polyester-sugar copolymer directs the micelle-nucleic acid complex to cells in vivo. Additional copolymers with similar properties may also be included. The composition improves delivery efficiency by providing a particulate gene carrier for which particle size and charge density are easily controlled by multivariate means. Various kinds of ligands and other functional compounds may be also be introduced using the composition. The composition may be used in a method for transforming a targeted host cell with a selected nucleic acid.

The present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan since the water soluble chitosan itself can combined with DNA having a negative electric charge(−) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof. Therefore, a water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention can effectively envelope paclitaxel by introducing hydrophilic and hydrophobic groups in the position of highly reactive amine group of the water-soluble chitosan. A water soluble chitosan nanopaclitaxel prepared as the above has an excellent re-dispersion force, after freeze-drying, in distilled water and has an outstanding anticancer effect with its accumulation in tumor cells greater than that of the other anticancer agent carriers.

Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle gene carriers also contain one or more mucus resistant polymers. In a particularly preferred embodiment, the nanoparticle gene carrier is a nanoparticle formed from one or more nucleic acids, PEI, and a mucus-resistant/diffusive graft copolymer composed of a PEI backbone functionalized by one or more PEG side chains. The nanoparticle gene carriers can efficiently diffuse through CF mucus, and can effectively serve as a vehicle to administer one or more nucleic acids to a patient suffering from CF.

The invention provides recombination interferon (rSIFN-co) or the functional analog with new space conformation, enhanced effect, and low side effect. It is showed by the external pharmacodynamics, it can not only restrain the DNA replication of the hepatitis b virus, but also restrain the exudation of the surface antigen (HBsAg) and e antigen (HBeAg). The cytology toxicity is 1/8 of the clinical interferon and the antiviral activity is 5-20 times to the clinical interferon and has a higher, a more board spectrum and longer time biological response reaction, and prevent the tumor hyperplasia and transmission. The invention also provides the synthetic gene code, gene carrier, expression system of the synthetic gene of the recombination interferon or the functional analog. Finally, the invention also provides the preparing method and application thereof.

The invention relates to polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, a preparation method thereof and application thereof. The preparation method comprises the step of directly condensing carboxyl in the polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine segmented copolymer with amino in polyethyleneimine to form the graft copolymer. The copolymer is a polycation gene carrier, integrates the advantages of polyethylene glycol, Makrolan and polyethyleneimine, and has high transfection efficiency, wherein the highest transfection efficiency to the medium luciferase plasmid of african green monkey kidney cell is 14 times of that of American Invitrogen biological company transfection reagent Lipofetamine<TM>2000, can effectively antagonize the inhibiting effect of blood serum to the transfection, and has less cell toxicity, wherein consistency thereof is not higher than 200 microgramme/ml and cell survival rate is more than 80%.

The invention provides gene transfer compositions using as the gene carrier a biodegradable polymer that contains one or more cationic alpha amino acids, such as arginine or agmatine. The compositions form a tight soluble complex with a poly nucleic acid suitable for transfecting target cells to effect translation of the cargo poly nucleic acid by the target cell. Thus, such compounds are useful both in vitro and in vivo.

The present invention provides a biocompatible and biodegradable elastomer, comprising a hard segment and a soft segment. The hard segment is formed by reacting diisocyanate and a chain extender; and the soft segment is comprising a biodegradable oligomer diol, wherein the biodegradable oligomer diol is selected from the group consisting of polycaprolactone diol, polyethylene butylene adipate diol (PEBA diol), poly-L-lactic acid diol (PLLA diol), polylactic acid diol and any combination thereof. The biocompatible and biodegradable elastomer of present invention can be used to produce vascular graft, cell carrier, drug carrier or gene carrier.

The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.

The invention provides a method of detection of transcription factor expression activity by a luciferase reporter gene system; the method comprises the steps: based on the luciferase characteristics of being lasting, stable and easy to detect, co-transfecting cells with a luciferase reporter gene vector containing a target gene promoter and a transcription factor expression plasmid; after the cells are cultured, carrying out lysis of a certain number of cells with a cell lysis buffer liquid, collecting a lysate containing luciferase, and centrifuging to take a supernatant; and then real-timely detecting luciferase expression intensity data in a luciferase activity detection buffer liquid, at the same time, detecting the luciferase concentration, correcting, and then calculating to obtain the transcription factor expression quantity, namely the transcription factor expression activity needing to detection. The method is simpler and more feasible in whole operation process, shorter in time consuming, higher in flux, relatively high in repeatability and accuracy, and lower in operating costs, thereby having broad application prospects, and having excellent market potential.

The invention discloses a target quaternary ammonium salt cationic polymer lipid gene carrier, a preparation method and an application thereof. The target quaternary ammonium salt cationic polymer lipid genetic carrier is characterized in that: a polymeric quaternary ammonium salt and lipid are adopted for preparing a quaternary ammonium salt cationic polymer lipid genetic carrier according to a mass ratio, wherein the mass ratio of the polymeric quaternary ammonium salt to the lipid is 0.05-20:1; then a assembly method or a modification method is adopted for modifying to prepare a folic acid or EGFR antibody modified cationic polymer lipid gene carrier. Results of gene transfection experiments show that: gene transfection efficiencies of the target quaternary ammonium salt cationic polymer lipid gene carrier in 293T cells and NIH-3T3 cells are the same as the gene transfection efficiencies of positive control lipofectamine of lipofectamine<TM>2000 in the 293T cells and the NIH-3T3 cells; the gene transfection efficiencies of the EGFR antibody modified cationic polymer lipid genetic carrier in liver cancer Huh-7 cells and breast cancer MCF-7 cells are higher than the gene transfection efficiencies of the lipofectamine<TM>2000 in the liver cancer Huh-7 cells and the breast cancer MCF-7 cells. The cationic polymer lipid genetic carrier system provided by the present invention has good biocompatibility and low cytotoxicity, and can be as an excellent non-viral gene delivery carrier.

The present invention provides targeted delivery systems to deliver pharmaceuticals to irradiated tissue comprising a biomolecule carrier, a targeting moiety to cellular adhesion molecules and a pharmaceutical. The present invention also provides methods of selectively targeting endothelial tissue for delivery of a pharmaceutical thereto and of treating a pathophysiological state in an individual using the targeted delivery systems disclosed herein. Further provided is a method of optimizing an immunoliposome for specific targeting of a pharmaceutical encapsulated therein to irradiated tissue by selecting a liposome that has a greater rate of adhesion to the irradiated tissue than a rate of uptake by the reticuloendothelial system.

The invention discloses an anti-CD19 engineering antibody and its application which is used in target direction combining lymphocytic leukemia cell. It lays a foundation for the next trituration genetic engineering medicine of the target direction therapy leukemia. It relates to anti-CD19 monoclonal antibody HI19a heavy and light chain variable region gene, and application of the gene code polypeptide, the gene carrier, and using the gene and polypeptide to make leukemia therapy medicine. The heavy and light chain variable region gene is come from the anti-CD19 monoclonal antibody HI19a. The invention successfully adopts gene engineering technique to make anti-CD19 gene engineering antibody, and lays a foundation for the target direction therapy of the leukemia.

The invention discloses nitrilase from brassica rapa, encoding genes and an application of the encoding genes to the preparation of pregabalin chiral intermediate (S)-3-cyan-5-methylhexanoic acid through biocatalysis, and an amino acid sequence of the nitrilase is shown as SEQ ID NO:1. The invention provides novel nitrilase for preparing the (S)-3-cyan-5-methylhexanoic acid with high region and high stereoselectivity through hydrolysis, the concentration of hydrolysis substrates of the nitrilase can reach more than 1 M, and an ee (enantiomeric excess) value is kept more than 99 percent. The pregabalin important chiral intermediate (S)-3-cyan-5-methylhexanoic acid can be prepared through the nitrilase; a preparation method of the (S)-3-cyan-5-methylhexanoic acid has the advantages of high atom economy, mild conditions, environmental friendliness and the like and has high industrial application potential.

Disclosed are low-molecular weight, water-soluble chitosan nanoparticles with folic acid conjugated thereto as a target ligand and a preparation method thereof. The nanoparticles can be simply prepared since the strong reactivity of the chitosan allows folic acid to be readily introduced thereinto. Also, the folic acid-conjugated, low-molecular weight, water-soluble chitosan nanoparticles can be useful as gene carriers because they are of low or zero-toxicity, have sizes suitable for use as gene carriers, can readily form complexes with DNA, allow high gene expression rates, and are excellent in targeting tumor cells which are rich in folic acid receptors.

The invention relates to the field of gene carriers, and particularly discloses a target type polypeptide nanometer gene carrier compound. The target type polypeptide nanometer gene carrier compound is prepared from a nano gene carrier with positive charges, a gene medicine and a tumor targeted antibody, wherein the nano gene carrier is adsorbed with the gene medicine and the tumor targeted antibody; and the nano gene carrier is prepared by coupling polypeptides with hydrophobic functional molecules. According to the target type polypeptide nanometer gene carrier compound, the nano gene carrier is formed by self-assembling and carries small interfering nucleic acid; the surface of the nano gene carrier is adsorbed with the tumor tissue targeted antibody; the nano gene carrier with the rich positive charges is used for adsorbing the targeted antibody with negative charges, so that the nano gene carrier with the positive charges can be cleared away in vivo circulation, and the targeting capacity can be also improved. The method is simple in process, mild in reaction conditions and easy to operate. Moreover, no covalent bonds are generated in the self-assembling process, so that no reverse reaction is caused, and highly ordered nano structures can be formed; and the target type polypeptide nanometer gene carrier compound is particularly suitable for constructing a biological medical material.

A transgenic carrier with deal targets (fibroblast growth factor receptor and integrant) is composed of the polypeptide CR16 specifically linked with alkaline fibroblast growth factor receptor, the polypeptide CP9 specifically linked with integrant, and the transgenic non-virus carrier system of CR16/CP9/cationic polymer PEI/exogenous DNA. Said carrier can effectively introduce the exogenous DNA to the tumor cell line and tumor tissue with high expression of FGFRs, so suppressing the growth of tumor. It can be used to preparation of the medicine for treating tumor and other diseases.

The invention discloses a synthesizing method of phosphocholine chitosan derivant, which comprises the following steps: reacting chitose powder and disubstituted Choline phosphonate with different proportions in the composite system of alkaline, carbon tetrachloride and secondary alcohol at 0-40 Deg C for 12-24h; hydrolyzing through alkaline liquid to obtain the product with different coupling rate. The invention modifies biological function and compatibility, which can be applied in the drug and gene carrier, tissue engineering rack, biological medical film, aquagel and biological intelligent instrument domain.

The invention discloses a preparation method of hyaluronic acid and chitosan composite nanofibers. According to the preparation method, natural products, namely the chitosan and the hyaluronic acid are used as raw materials, and the composite polyelectrolyte nanofibers are prepared by preparing a soluble composite polyelectrolyte mixture solution from the chitosan and the hyaluronic acid and adopting a high-pressure electrostatic spinning technology. The nanofibers prepared by adopting the preparation method disclosed by the invention have the property that the charge carrying property can beadjusted by means of the pH value, that is to say, the hyaluronic acid is ionized to carry negative charges under an alkaline condition, and the chitosan is protonized to carry positive charges underan acidic condition. The nanofibers have good application prospects in the aspects of biological tissue engineering, medicament or gene carrier materials, biomedical materials and the like.